{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-017822","form_type":"8-K","ticker":"CYTK","cik":"0001061983","company_name":"CYTOKINETICS INC","filed_at":"2023-05-04T23:59:59+00:00","discovered_at":"2026-05-14T18:03:37.817068+00:00","generated_at":"2026-06-15T19:42:30.563872+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Cytokinetics Q1 net loss widens to $131.3M; omecamtiv CRL; cuts spend 10%","bullets":["Net loss of $131.3M ($1.38/shr) vs $89.4M ($1.05) in Q1 2022; revenue $4.6M (up from $1.1M).","Cash $704.4M; plans to reduce 2023 spending >10% to maintain >2 years cash runway.","FDA issued Complete Response Letter for omecamtiv mecarbil NDA; EMA MAA review ongoing.","SEQUOIA-HCM enrollment nearly complete; top-line results expected Q4 2023.","COURAGE-ALS met futility criteria; company discontinuing reldesemtiv treatment."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-017822","json":"https://secwatch.observer/filing/0000950170-23-017822.json","markdown":"https://secwatch.observer/filing/0000950170-23-017822.md","text":"https://secwatch.observer/filing/0000950170-23-017822.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1061983/000095017023017822/0000950170-23-017822-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1061983/000095017023017822/cytk-20230504.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T19:42:30.563872+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"13bc1add90db444f233ae1abcff68b8699fc35a5","claim":"CYTOKINETICS INC reported the first quarter ended March 31, 2023 results: net income $131.3 million, EPS $1.38 per share.","evidence_excerpt":"Net loss for the first quarter was $131.3 million, or $1.38 per share, compared to net loss for the first quarter of 2022 of $89.4 million, or $1.05 per share.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1061983/000095017023017822/0000950170-23-017822-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the first quarter ended March 31, 2023"},{"label":"Net income","value":"$131.3 million"},{"label":"EPS","value":"$1.38 per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}